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Abstract Tremendous advances have been made in
understanding the pathophysiology and treatment of con-
gestive heart failure (CHF). However, diagnosis still remains
difficult, even with a comprehensive physical examination.
Symptoms such as dyspnea are non-specific and poorly
sensitive indicators for early CHF that can be largely unde-
tected. The discovery of natriuretic peptides (BNP) as
diagnostic biomarkers has been one of the most critical
advances for heart failure diagnosis. Therefore, both B-type
and N-terminal pro-B-type have potential role in the diag-
nosis of heart failure, as well as in prognostic risk assess-
ment. A single determination of BNP at any time during the
progression of chronic HF provides a clinically useful tool
for risk stratification. The hypothesis that repeated mea-
surements might carry prognostic information beyond a
single measure was confirmed in different settings. One of
the main interests is given to the values of repeated deter-
minations for monitoring progression of disease, and for the
evaluation of the clinical effects of medical therapy. Nev-
ertheless, despite thousands of papers describing their
potential utility, current guidelines have not endorsed the
highest level of recommendation for their use, in part,
because the application in clinical practice is often limited
for the absence of well codified cut off. Recently, European
guidelines emphasized the role of natriuretic peptides as
potential laboratory markers. In the near future, algorithm
building will take into consideration clinical and echocar-
diographic parameters as well as NP measurements, and this
may lead to a correct diagnosis and identification of
patients at high risk. The purpose of this review is to discuss
the clinical approaches and future applications of natriuretic
peptides in heart failure and coronary disease.
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Introduction
Several studies have suggested the need for new diagnostic
capabilities, especially with the increasing prevalence of
heart failure in the United States. One of the biggest hopes for
utilizing biomarker testing is to determine the level of dis-
ease severity as a means to triage medical decisions as well as
to monitor their responses. Early diagnosis is very important
for a better therapy optimization and to improve the out-
comes. However, identification is often difficult because of
symptoms aspecificity, and the lack of a gold standard pro-
tocol to make the correct diagnosis. After traditional first line
evaluations (ECG, thorax radiography and clinical exami-
nation), echocardiography is the technique recommended for
patients affected by heart failure, thanks to its easy avail-
ability and practicability. Although most studies show that
brain natriuretic peptide (BNP) is a marker with a high
sensitivity and specificity, application in clinical practice is
often limited because of the absence of a well codified cut off
in the dosage concentration. Confusing factors, including
age, race, obesity, and renal dysfunction, may complicate the
clinical interpretation of circulating BNP levels in patients
with chronic and stable congestive heart failure (CHF), and
should be considered when patients are evaluated. However,
there is good concordance between presence of heart failure,
its severity and elevated natriuretic peptide (NP) levels: high
BNP levels are related to high ventricular dysfunction degree
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and more advanced CHF stages. Serial measurements of BNP
in the chronic outpatient setting appear to convey additional
prognostic value for relevant adverse outcomes, including
death or destabilization of CHF requiring hospitalization, and
they are thus recommended in clinical practice.
Past and current heart failure diagnostic criteria
Accurate diagnosis of heart failure can be difficult in the
absence of diagnostic tools with high sensitivity and
specificity. The diagnosis of CHF in primary care is con-
firmed by clinical and instrumental evaluation in about
25–50% of cases. The accurate clinical diagnosis of CHF is
limited by several causes: poor indicative signs and
symptoms, as well as use of diagnostic tools with low
sensibility and specificity. Every single sign or symptom
has only mild accuracy: for example, fatigue and peripheral
edema are, respectively, present in 60 and 40% of cases.
Common tests frequently used are poorly sensitive: most
often chest radiography is not able to demonstrate venous
hypertension or early interstitial edema particularly in
patients with chronic heart failure. Similarly the ECG does
not have specific CHF signs (specificity 61%, sensibility
93%) Furthermore, low use of echocardiography in the
Emergency Department (ED) and lack of diagnostic indi-
ces of decompensated CHF with preserved ejection frac-
tion could lead to underestimated or late diagnosis.
International guidelines encourage the use of more objec-
tive diagnostic tools for etiologic identification and con-
sequential-specific therapeutic approach. Past guidelines
recommend aECG, chest X-ray study, laboratory tests, and
echocardiogram as a reasonable workup, leaving a mar-
ginal role for BNP. The last European guidelines instead,
on the basis of numerous scientific papers that demonstrate
the high prognostic value of NP, put their measurement at
the center of the diagnostic algorithm. In fact, evidence
exists supporting their use for diagnosing, staging, making
hospitalization or discharge decisions, and identifying
patients at risk for adverse clinical events. High levels of
BNP despite optimal treatment indicate a poor prognosis
[1]. A BNP level below 100 pg/ml suggests a need for
revision of the diagnosis, values of BNP between 100 and
400 pg/ml require echocardiographic and other examina-
tions to confirm the heart failure diagnosis; while BNP
values above 400 pg/ml are associated with a worse out-
come and a high accuracy [2] (Table 1).
Natriuretic peptides in heart failure diagnosis
Despite advances in diagnosis and treatment, heart failure
remains a growing medical problem associated with major
hospitalization, hospital mortality, recurrent admissions
and a poor prognosis. In the clinical setting, natriuretic
peptides are widely utilized as a first-line diagnostic
complement to clinical and radiographic data, thereby
reflecting the correct diagnosis and the disease’s severity
[3]. The dosage of BNP, a hormone that is produced
mainly by the heart ventricles, is a useful test for CHF
diagnosis with high sensitivity and specificity and strong
positive predictive values. BNP is synthesized in the heart
as a reaction to cardiac wall distension and stretching and
neurohormonal activation. BNP leads to natriuresis and
vasodilatation activation with concomitant inhibition of
the renin angiotensin system and adrenergic activity.
After synthesis, the peptide is cleaved first to pro-BNP,
then to the biologically active form and the inactive
aminoterminal fragment, NT pro-BNP. BNP plasma levels
increase results in improved myocardial relaxation, and
plays an important regulatory role in response to acute
increases in ventricular volume by opposing the vaso-
constriction, sodium retention, and antidiuretic effects of
the activated renin–angiotensin–aldosterone system.
Plasma BNP levels are elevated in patients with acute
myocardial infarction and left ventricular dysfunction; this
increase persists during the late phases of cardiac
remodeling [4]. Elevated peptide levels are directly cor-
related with prognosis, and they are directly proportional
to NYHA class, intra-ventricular pressure, pulmonary
pressure, and inversely to cardiac output [5]. Plasma BNP
levels are raised in several conditions with wall stress
increase: hypertrophic cardiomyopathy, diastolic dys-
function and left ventricular hypertrophy. In all these
circumstances, BNP levels appear related to myocardial
mass index, interventricular and posterior wall thickness
[6]. Several studies confirm the utility of BNP levels in
patients presenting with acute dyspnea. In a large study,
BNP levels were measured in 321 patients: patients with
heart failure have higher hormone levels, as opposed to
patients with dyspnea due to respiratory diseases [7].
Dentali et al. [8] emphasize the correlation between BNP
and increased pulmonary hypertension, such as in pul-
monary embolism. The first multicenter study ‘‘Breathing
Table 1 Causes that altered plasmatic natriuretic peptide levels
Cardiac Non-cardiac
Heart failure Acute pulmonary embolism
Systolic dysfunction Pulmonary hypertension
Diastolic dysfunction Anemia
Coronary artery disease Cor pulmonale
Hypertension with LVH Renal insufficiency
Valvular heart disease Septic shock
Atrial fibrillation Hyperthyroidism
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not Properly Study’’, enrolled 1,586 patients in the ED:
they all had acute dyspnea, and had BNP measurement.
The gold standard for CHF was adjudicated by two
independent cardiologists unaware of the laboratory
results, who reviewed all the clinical data and standard-
ized scores. BNP values correlated with NYHA functional
class: a linear correlation was seen among patients in
NYHA I (197 pg/ml) compared to patients in NYHA IV
(978 pg/ml) [9]. Several parameters like high venous
pressure recruitment, increase of left ventricular dimen-
sion and interstitial edema at chest radiogram were also
evaluated. They did not reveal a similar predictive power
accuracy as useful as BNP in the correct diagnosis
identification. BNP is a good marker not only for diag-
nosis, but also for the CHF severity with linear value
increasing in relation to the stage. The levels of BNP are
also correlated with some echocardiographic parameters
of both ventricular systolic and diastolic dysfunction [10–
14]. Whereas the prognostic value of BNP in patients
with impaired left ventricular systolic function is well
documented, there are fewer data for the population of
patients with chronic HF and preserved systolic function.
In a prospective study that included 161 patients, the
probability of death within 12 months after hospital
admission was predicted by plasma levels of pro-BNP in
patients with systolic dysfunction as well as in patients
with preserved systolic function [15] (Fig. 1).
Natriuretic peptides in ACS
Acute coronary syndromes (ACS) without ST elevation is
an heterogeneous group of events, ranging from stable
angina pectoris to myocardial infarction in which there is
an important increase in troponin and isoenzyme MB
creatine kinase. Risk stratification is characterized by
clinical history and examination, electrocardiographic
characteristics, markers of myocardial damage, but it
remains relatively unspecified [16]. Diagnostic and prog-
nostic value of NT pro-BNP and BNP appears similar to
CHF, but it is different for ACS. BNP or BNP-related
marker is used for the diagnosis of patients suffering from
acute coronary syndrome, the level of BNP, or a marker
related to BNP, unstable angina, non-ST-elevation non-Q
wave myocardial infarction, ST-elevation, non-Q wave
MI [17, 18]. However, a progressive increase in BNP
levels in relation to the extent of coronary disease has
been demonstrated. For example, patients with descending
anterior coronary disease show the highest level of BNP.
In patients with unstable angina, non-ST elevated myo-
cardial infarction (UA/NSTEMI), elevated BNP levels
have been demonstrated to be strongly associated with an
increased risk of adverse outcome. Because of its release
in response to increased ventricular chamber pressure or
wall tension, in UA/NSTEMI patients with manifest heart
failure or a decreased LV ejection fraction, elevated BNP
reflects a great degree of myocardial dysfunction, asso-
ciated with a greater risk of death and recurrent CHF. In
particular, the strong association of BNP levels and
mortality even among patients without myocardial
necrosis indicates that BNP and NT pro-BNP may reflect
the extent of severity of the ischemia, even in the absence
of an irreversible injury. Ezekowitz et al. in the COMMA
study measured the NT pro-BNP at baseline, 24 and 72 h
after presentation with acute STEMI. They show that
BNP is an independent predictor of poor outcome and
Clinical examination, ECG, Chest X-
ray, Laboratory examination, blood 
gasses analysis
BNP and NT-proBNP dosage
BNP< 100 pg/ml
NT-proBNP < 400 pg/ml
BNP 100-400 pg/ml
NT-proBNP 400-2000
BNP> 400 pg/ml
NT-pro BNP >2000 
pg/ml
HF unlikely
HF uncertain
Need Echocardiographic 
evaluation
High HF probability
Fig. 1 BNP algorithm for
diagnosis of acute heart failure
(modified by ESC guidelines
2008)
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adds clinically useful prognostic information. In post-MI,
BNP measurement is able to predict adverse ventricular
remodeling and enlargement together with future cardiac
events [19].
Natriuretic peptide and outcome
In CHF patients, BNP measurement appears very important
for risk stratification; in fact, high levels are associated
with recurrent hospitalization and risk of sudden death
[20]. Several studies that have used natriuretic peptides
predischarge suggest as well that the BNP level appears to
be the strongest predictor for identifying subsequent death
or hospital admission at 6 months [21–23]. In patients with
coronary disease and preserved ventricular function, BNP
gives strong prognostic data over traditional risk factors
[24]. The best evidence of the prognostic value of BNP in
chronic CHF comes from statistically robust controlled
clinical trials that include a large number of clinically well-
characterized patients from different sites. The first data on
pro-BNP from such a trial came from the Australia–New
Zealand Heart Failure Group [25]. In approximately 300
patients with well-characterized chronic CHF of ischemic
etiology (left ventricular ejection fraction, LVEF, \0.45)
randomized to receive carvedilol or placebo, levels of NT
pro-BNP above the median were associated with increased
risks for new decompensated CHF events [relative risk
(RR) 4.7, 95% confidence interval (CI) 2.2–10.3] and all-
cause mortality (RR 4.7, 95% CI 2.0–10.9) during
18 months of follow-up, independent of age, NYHA
functional class, LVEF, previous myocardial infarction, or
previous HF admission. The Valsartan heart failure (Val-
HeFT) trial, 5,010 patients (85% with blood samples col-
lected at study entry) with mild-to-moderate chronic CHF
receiving recommended medical therapy, was randomized
to an angiotensin II type 1 receptor blocker or placebo [26].
An increment of 500 ng/l above the baseline concentration
of NT pro-BNP carries an increased adjusted risk of 3.8%
for mortality and 3.0% for hospitalization for CHF. On
multivariate analysis, pro-BNP ranks as the best prognostic
factor in these patients again, independent of and more
powerful than traditional risk factors, such as NYHA class,
age, left ventricular dilation, or renal dysfunction [27]. A
single determination of NT pro-BNP at any time during the
progression of chronic CHF provides a clinically useful
tool for risk stratification. The Val-HeFT study shows BNP
to be prognostically superior to several other recognized
neurohormonal markers of risk in HF, including norepi-
nephrine, renin activity, aldosterone, and endothelin l, and
echocardiographic variables. As with acute CHF, the
hypothesis that repeated measurements carry prognostic
information beyond a single measure has been confirmed in
different settings. The value of repeated determinations of
NT pro-BNP levels appear very important for monitoring
progression of disease, and may help in evaluating the
clinical effects of medical therapy. The importance of
natriuretic peptides for risk stratification in patients with
acute coronary syndrome, encompasses both BNP and NT
pro-BNP; both peptides show independent and incremental
prognostic value above traditional diagnostic tools and
conventional risk markers, such as the ECG and bio-
chemical risk indicators, such as troponin. A recent report
shows that elevated levels of BNP predict a two- to
threefold increased risk of death by 10 months.
Future perspectives and application in clinical practice
There are increasingly convincing data that correlate the
measurement of NP with heart failure diagnosis and prog-
nosis. Higher values of BNP are associated with a worse
outcome and a greater degree of left ventricular dysfunction.
For these reasons, BNP should be considered a powerful tool
that can help the physician in diagnosis, prognosis, and
treatment of decompensated patients from admission to
hospital discharge. BNP is a useful tool to assess risk strat-
ification and predict myocardial ischemia in ACS. In patients
with non-ST elevation myocardial infarction (NSTEMI), the
magnitude of the risk relationship associated with natriuretic
peptides seems to be higher than associated with other
markers. In these clinical conditions they represent markers
for left ventricular dysfunction and enlargement as well as
for coronary disease extension. However, we must consi-
derer the presence of confounding factors that can alter the
plasma NP values. In these cases, others biochemical
markers, echocardiography and other tools can identify with
better accuracy patients with heart failure or acute coronary
disease. Furthermore, several interesting small molecules
(such as galectin-3, copeptin, metalloproteinases, and many
others) have already provided some evidence of risk strati-
fication in patients with acute heart failure or post-myocar-
dial infarction [28, 29].
Conclusions
Natriuretic peptide levels are strictly correlated with CHF
severity. They are found to correlate with the severity of
left ventricular systolic dysfunction, right ventricular dys-
function and pressures, and left ventricular filling alter-
ation. As well as in CHF in ACS with or without ST
elevation, NP was appearable to predict severity of coro-
nary disease and ischemic area extension. For the above
reasons, and the ability to give additional prognostic
information with respect to traditional biomarkers (i.e.
66 Intern Emerg Med (2011) 6:63–68
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troponin and C-reactive protein), natriuretic peptides are
candidates for utilization in the setting of principal risk
scores.
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